How many GLP-1 pills are there now?

Three oral semaglutide or GLP-1 products are on the US market, but only two are approved for weight management. The Wegovy pill (oral semaglutide) launched in January 2026 for chronic weight management. Foundayo (orforglipron) was approved April 1, 2026 for the same purpose. Rybelsus is oral semaglutide approved for type 2 diabetes, not for weight loss.

What is the practical difference between them?

The dosing routine, and it is a big one. Both semaglutide pills — the Wegovy pill and Rybelsus — must be taken in the morning on an empty stomach with no more than 4 oz of plain water, followed by at least a 30-minute wait before eating, drinking anything else, or taking other oral medications. Foundayo has no such restriction: Lilly describes it as able to be taken any time of day, with or without food.

Why does semaglutide need an empty stomach but orforglipron does not?

Semaglutide is a peptide, and peptides are broken down by digestion. Oral semaglutide is formulated with an absorption enhancer that only works reliably on an empty stomach with minimal water. Orforglipron is a non-peptide small molecule, so it survives digestion like an ordinary tablet and does not depend on those conditions.

Which one produces the most weight loss?

We would not rank them confidently from the published data. Lilly reports orforglipron producing 11.1% average weight loss at its top 17.2 mg dose over 72 weeks. Injectable semaglutide produced about 14.9% at 68 weeks in STEP 1, but that is the injection rather than the pill, and cross-trial comparisons between different populations and protocols are indicative rather than decisive. Ask your prescriber about what the data supports for your situation.

Can I take Rybelsus for weight loss?

Rybelsus is approved for type 2 diabetes, not for chronic weight management. A clinician may prescribe medications off-label at their discretion, but that is a decision for them to make and explain — and with two oral options now approved specifically for weight management, the reason to reach for Rybelsus instead is a question worth asking.

Are the pills cheaper than the injections?

At starting doses, yes. NovoCare Pharmacy lists the Wegovy pill from $149/month against $199 for the pen, and LillyDirect lists Foundayo from $149 against $299 for Zepbound. But both pill prices are dose-limited introductory offers — Walgreens publishes the Wegovy pill rising to $299 and Foundayo to $199–$299 at higher doses. Budget for the dose you expect to reach.

Do the pills have fewer side effects?

Not inherently. These are the same drug class acting on the same receptors, and gastrointestinal effects — nausea, diarrhea, constipation, vomiting — dominate the profile regardless of route. What a pill removes is injection-site reactions, needles, and cold-chain storage, not the class effects.

Oral GLP-1 Pills Compared: Wegovy Pill vs Foundayo vs Rybelsus

The three options at a glance

	Wegovy pill	Foundayo	Rybelsus
Drug	Oral semaglutide	Orforglipron	Oral semaglutide
Type	Peptide	Non-peptide	Peptide
Approved for weight loss	Yes	Yes	No — type 2 diabetes
Available since	January 2026	April 1, 2026	Earlier
Food rules	Empty stomach, ≤4 oz water, 30-min wait	None — any time, with or without food	Empty stomach, ≤4 oz water, 30-min wait
Frequency	Daily, morning	Daily, any time	Daily, morning
Self-pay from	$149/mo (NovoCare)	$149/mo (LillyDirect)	Not covered here

The 30-minute rule is the real dividing line

If you take away one thing, make it this. Both semaglutide pills carry the same routine, and it is more demanding than most people expect:

Taking oral semaglutide

• First thing in the morning, on an empty stomach
• With plain water only — no more than 4 oz (about half a glass)
• No other liquids
• Then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications

That last clause matters more than the fast itself. If you take a morning thyroid medication, a blood pressure tablet, or anything else that needs to go down with breakfast, you now have a sequencing problem to solve every single day — and adherence is the thing that determines whether any of this works.

Foundayo has none of these constraints. Lilly describes it as able to be taken any time of day, with or without food, and that is not marketing gloss — it follows directly from the chemistry.

Why the chemistry drives the difference

Semaglutide is a peptide, a chain of amino acids. Digestion exists precisely to break those down, which is why semaglutide is normally injected. Oral semaglutide gets around this with an absorption enhancer, but the workaround only performs reliably under narrow conditions: empty stomach, minimal water, nothing else competing.

Orforglipron is a non-peptide small molecule. It reaches the GLP-1 receptor by a different chemical route and survives digestion the way an ordinary tablet does. No absorption enhancer, no narrow conditions.

This is also why you should be sceptical of anyone describing all three as interchangeable “GLP-1 pills.” The mechanism at the receptor is comparable; how the drug gets there is not.

Rybelsus is the odd one out

Rybelsus is oral semaglutide approved for type 2 diabetes, not for chronic weight management. It shares the same empty-stomach routine as the Wegovy pill because it is the same molecule in a similar formulation.

A clinician can prescribe off-label at their discretion, and some do. But now that two oral options are approved specifically for weight management, “why this one instead?” is a fair question to put to a prescriber who suggests it — and the answer should be clinical rather than about availability or price.

What about efficacy?

This is where we will be less definitive than most pages you will find, because the honest answer is that the published data does not support a confident ranking.

Lilly reports orforglipron producing 11.1% average weight loss at its top 17.2 mg dose over 72 weeks in adults without diabetes. Injectable semaglutide produced about 14.9% at 68 weeks in STEP 1 — but that is the injection, not the pill, and comparing across trials with different populations, durations, and protocols gives you a direction rather than a verdict.

What we can say

Across this drug class the response is consistently dose-dependent, and injectable formulations generally deliver more drug to the bloodstream than oral ones. Expect the pills to sit below the top injectables on average weight loss. Expect individual variation to be wide enough that averages tell you relatively little about your own result. And treat any site presenting a clean league table of these medications as overstating what the evidence supports.

Cost

At starting doses, the pills are cheaper than the injections — which is a genuine reversal of how this market used to work.

NovoCare Pharmacy lists the Wegovy pill from $149/month for the 1.5 mg and 4 mg doses, against $199 for the injection pen.
LillyDirect lists Foundayo from $149/month, against $299 for Zepbound at its starting dose.

Both figures are dose-limited introductory offers, and this is where people get caught. Walgreens publishes the detail: the Wegovy pill rises to $299/month at higher doses, and Foundayo to $199–$299. Since the response is dose-dependent, most people aiming for meaningful weight loss will end up in those tiers rather than the advertised one.

If you have Medicare Part D, note that both the Wegovy pill and Foundayo are covered under the Medicare GLP-1 Bridge at a flat $50/month — which does not rise with dose.

Choosing between them

Foundayo may suit you better if:

• You take other morning medications that cannot wait 30 minutes
• Your mornings are irregular and a fixed fasting window is unrealistic
• You have tried oral semaglutide and abandoned the routine
• You want dosing flexibility across the day

The Wegovy pill may suit you better if:

• You already tolerate semaglutide well by injection
• A consistent morning routine is easy for you
• You are not taking a strong CYP3A4 inhibitor
• Your prescriber prefers a molecule with a longer track record

One interaction is worth flagging on the Foundayo side: its maximum dose drops to 9 mg once daily if you take a strong CYP3A4 inhibitor, and strong CYP3A4 inducers should be avoided. Because the response is dose-dependent, that can meaningfully change what you should expect. Give your prescriber a full medication list.

The bottom line

Needles are no longer the price of entry to this drug class, and for people who never started because of them, that is the whole story. But “a pill” is not one thing. Two of the three require a daily 30-minute fast that interacts with everything else in your morning; one does not. One is not approved for weight loss at all.

Pick on the basis of what you will actually take every day for years, then let your prescriber weigh that against your history and your other medications. A medication you take consistently at a modest dose beats one you abandon at a higher one.

The GLP-1 Pills, Compared